Dynavax Technologies Corporation
Dynavax Technologies — Q4 2024 Earnings Presentation
22 slides from Dynavax Technologies's earnings presentation, Feb 20, 2025
Slide 1: Corporate Presentation
Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases February 2025 Nasdaq: DVAX
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market
Slide 3: Dynavax Core Strategic Priorities
Drive Growth in HEPLISAV-B • Achieve at least 60% total market share by 2030 • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development Dynavax Advance Di
Slide 4: Executing on Our Strategy: FY 2024 Highlights
Executing on Our Strategy: FY 2024 Highlights HEPLISAV-B FY’24 net product revenue: HEPLISAV-B total U.S. market share (as of Q4’ 24): $268M, up 26% YoY vs. $213M in FY23 ~44% in Q4 ’24 vs. ~42% in Q4 ‘23 Achieved record annual HEPLISAV-B Q4’24 net product revenue: HEPLISAV-B net product $71M, up 39
Slide 5: CpG 1018 Adjuvant: Well-defined MoA and Clinical Profile
CpG 1018® Adjuvant: Well-defined MoA and Clinical Profile Proprietary CpG 1018 Mechanism of Action Clinically Proven Profile adjuvant selectively and • CpG 1018 adjuvant is a • Faster and consistently higher rates optimally activates TLR9 – synthetic form of DNA that of protection in HEPLISAV-B, an
Slide 6: HEPLISAV-B
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] © Copyright DYNAVAX 2025 6|
Slide 7: HEPLISAV-B Clinical Outcomes
Primary Endpoint Results: HEPLISAV-B Study 2 per protocol population (ages 40-70)1 Primary Primary Clinical Outcomes 100% (N=1,482) endpoint endpoint 90% Higher and faster rates of protection 80% HEPLISAV-B provided significantly higher rates of protection than Engerix-B 70% at every time point in c
Slide 8: Continued HEPLISAV-B Growth: Revenue & Market Share
Continued HEPLISAV-B Growth: Revenue & Market Share Sequential Q4 HEPLISAV-B HEPLISAV-B Vaccine Annual Net 300 Total U.S. Market Share1 Product Revenue ($M)2 Achieved record 50% 250 annual revenue in 2024 of $268M 44% 200 42% 150 40% 100 35% 50 36 62 126 213 268 30% 0 Q4'22 Q4'23 Q4'24 2020 36 2021
Slide 9: HEPLISAV-B Market Opportunity Expected to Grow to Over $900M in U.S. by 2030
HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 Peak Market Expanding Market Opportunity Through 2030 Durable Long Term Market Opportunity Maintained Through 2040 in 2030 Represents a double-digit CAGR for HEPLISAV-B product net sales out to 2030 >$900M • Ongoing penetr
Slide 10: HEPLISAV-B Market Opportunity Expected to Grow to Over $900M in U.S. by 2030
HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 HEPLISAV-B is the market share leader in projected largest growth segments (Retail and Prioritized IDNs) 2024 Market Size: ~$615 M1 2030 Projected Market Size: >$900 M2 Dialysis3 5% Prioritized IDN/ Dialysis3 Clinics4 6% 3
Slide 11: Vaccine Development Pipeline
Vaccine Development Pipeline Herpes Zoster (Shingles) | Plague © Copyright DYNAVAX 2025 11 |
Slide 12: Shingles Program: New Options Needed
Shingles Program: New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 Herpes Zoster (shingles) is an extremely painful consequence Program Status: of the reactivation of a latent varicella-zoster virus (VZV), the same virus that causes varicella (chickenpox). Recent Upd
Slide 13: Shingles Program: Path to Establishing Proof-of-Concept
Shingles Program: Path to Establishing Proof-of-Concept for a Differentiated and Best-in-Class Shingles Vaccine Key Trial Objectives / Next Steps PHASE 1 PHASE 1/2 FUTURE DEVELOPMENT CLINICAL TRIAL CLINICAL TRIAL Established initial proof-of-principle for o Establish proof-of-concept (PoC) for a o A
Slide 14: Shingles Program: Z-1018 Improved Tolerability and Similar Immunogenicity vs Shingrix
Shingles Program: Z-1018 Demonstrated Improved Tolerability and Similar Immunogenicity Compared to Shingrix in Phase 1 Tolerability Immunogenicity Rate of moderate/severe Vaccine Response Rate (VRR)2 Post Injection Reactions (PIRs)1 Local PIRs Systemic PIRs Anti-gE Antibodies CD4+ T-cells 100 100 80
Slide 15: Plague Program
Plague Program Phase 2 program conducted in collaboration with, and funded by, the U.S. DoD Program Status: Government agencies research and stockpile medical Recent Updates: countermeasures – biologics, drugs, devices – which may be used in the event of a potential public health emergency • Based o
Slide 16: Financial Highlights
Financial Highlights © Copyright DYNAVAX 2025 16 |
Slide 17: Q4 and FY 2024 Financial Summary
Q4 and FY 2024 Financial Summary Financial Results ($ millions) Q4 2024 Q4 2023 % Change FY 2024 FY 2023 % Change Total Revenues 72.0 55.6 30% 277.2 232.3 19% HEPLISAV-B Net Product Revenue 71.1 51.1 39% 268.4 213.3 26% Other Revenue 1.0 4.5 -78% 8.8 19.0 -54% Cost of Sales - Product 13.4 8.7 54% 49
Slide 18: Creating Value through Disciplined and Balanced Capital Allocation Strategy
Creating Value through Disciplined and Balanced Capital Allocation Strategy Our capital allocation priorities include: 01 02 03 04 Maximizing Investing in Accessing late- Opportunistically HEPLISAV-B pipeline leveraging stage assets in return capital to through targeted CpG 1018 infectious diseases
Slide 19: Providing Full Year 2025 Financial Guidance
Providing Full Year 2025 Financial Guidance1 HEPLISAV-B Adjusted EBITDA 3 Net Product Revenue (Excluding stock-based compensation) $305 M - $325 M > $75 M Up 17% YoY 2 Up 45% YoY 1. FY 2025 financial guidance based on the Company’s current operating plan as of February 20, 2025 2. The percent change
Slide 20: Dynavax Core Strategic Priorities
Drive Growth in HEPLISAV-B • Achieve over 60% total market share by 2030 • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development Dynavax Advance Differ
Slide 21: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations © Copyright DYNAVAX 2025 21 |
Slide 22: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
DYNAVAX TECHNOLOGIES CORPORATION RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA (In thousands) (Unaudited) Three Months Ended Year Ended December 31, December 31, 2024 2023 2024 2023 GAAP Net income (loss) $ 7,050 $ 219 $ 27,309 $ (6,389) Adjustments: Depreciation & Amortization 374 375